Search results for: 'endpoint security GLOBAL'

Pharmaceutical drug discovery and development processes suffer from declining success rates and a stagnant pipeline. Artificial Intelligence (AI) supported by Big Data could be a key element that can provide an effectual solution. There has been a rapid growth in the data generated within the life sciences and pharmaceutical industries. This stems ...

Full product development IVD CMO comprises companies that partner with OEMs and support them in the development of IVD devices, ranging from concept to commercialization. IVD companies are continuously looking at new ways to optimize resources due to rising cost pressures and regulatory complexities, prompting industry participants to adopt innovat...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive view of industry context, drivers, restraints, and ...

This issue of Vital Signs discusses the change in 2015 Mammogram Guidelines, NeoGenomics' acquistion of Clarient from GE, and Tute Genomics' acquisition of Knome.

The Asia-Pacific next-generation diagnostics market's revenue is projected to decline by 5.0% in 2023, attributed to the reduced demand for COVID-19-related testing. Rapid expansion in non-COVID molecular diagnostics and point-of-care testing (POCT) will not be sufficient to drive the overall recovery of the region. As companies continue to focus o...

The COVID-19 pandemic prompted a transformation in the infectious disease point-of-care testing (POCT) market. The shift towards miniaturized POCT devices will lead to the emergence of cost-effective integrated lab-on-a-chip devices based on microfluidic technologies and smartphone-based solutions enabling multiplexed detection of infectious pathog...

The healthcare landscape is experiencing a profound shift as it shifts away from traditional fee-for-service models toward value-based care. This transition emphasizes collaboration among healthcare stakeholders, fostering a patient-centric approach. The focus is not merely on the quantity of services delivered but also on the quality of care, enco...

Biomarkers are no longer mere tools used to measure the criteria of a biological process characteristic. They are being increasingly used in patient stratification and customised medical interventions. This research service presents an overview and analysis of the global biomarker market. It provides revenue forecasts for biomarker on technological...